Ebola | |||||
NEWS | |||||
Democratic Republic of Congo: Ebola Virus Disease - External Situation Report 94 1. Situation update. From 18 to 24 May 2020, no new confirmed cases of Ebola virus disease (EVD) have been reported in the Democratic Republic of ...
| |||||
A virus-hunter falls prey to a virus he underestimated Piot, 71, is a legend in the battles against Ebola and AIDS. But COVID-19 almost killed him. Advertisement. "A week ago, I ...
| |||||
The NHS will fight the coronavirus pandemic with the drug used for Ebola, reports confirm. The drug, called remdesivir, was developed for Hepatitis C aswell as Ebola, but initial trials on COVID-19 patients showed the reduction in symptoms.
| |||||
MSD unveils bid to tackle coronavirus pandemic ... is the basis for MSD's Ebola Zaire virus vaccine, Ervebo (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans.
| |||||
More top biosafety laboratories planned "Research on viruses such as SARS, H1N1, MERS, Ebola, H5N7 and the novel coronavirus needs to be conducted in P3 or P4 labs," said Zhou Haibo ...
| |||||
Viral vector vaccines and a nucleotide: Merck enters the COVID game ... using its recombinant vesicular stomatitis virus (rVSV) technology already proven in Merck's Ebola Zaire virus vaccine, Ervebo (Ebola Zaire Vaccine, ...
| |||||
UK COVID-19 deaths top 37000 as another 134 patients die The antiviral medicine was developed for Ebola, but initial trials on COVID-19 patients showed it could reduce recovery times by about four days.
| |||||
4 infectious diseases that should not be forgotten during COVID-19 ... in less than 20 years,through the vaccination of nearly 700 million children, - Gavi has most recently ensured a life-saving vaccine for Ebola.
| |||||
Five things for pharma marketers to know: Wednesday, May 27, 2020 The company will use the same virus technology used in its Ebola vaccine. The vaccine candidate is currently in preclinical development with clinical ...
| |||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
Receive this alert as RSS feed |
Send Feedback |
Tidak ada komentar:
Posting Komentar